Company intelligence / Profile preview

BWX Technologies

Ottawa/Kanata, Ontario, Canadabwxt.com ↗

Ownership: Private
Employees: ~4500
Development stage: Commercial

Overview

BWXT Medical manufactures cGMP-grade medical isotopes, APIs, and finished products used globally in diagnostic imaging and targeted radiotherapies. The company has established partnerships with leading biotechs to supply actinium‑225 for clinical-stage targeted alpha therapy programs. It operates large-scale facilities capable of supporting both clinical trials and commercial production.

Therapeutic areas: OncologyOther
Modalities: RadiopharmaceuticalActive pharmaceutical ingredient (API)Small molecule (for some isotopes used in radiolabeling)Device (for certain nuclear medicine applications)
Industry: Contract Manufacturing Organization

Partnerships

Fusion Pharmaceuticals (actinium‑225 supply)NorthStar Medical Radioisotopes (actinium‑225 production partnership)

Beyond the preview

Go deeper on BWX Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BWX Technologies.

Explore the full profile